A Multi-center, Double-blind, Randomized Phase III Clinical Trial of Chiauranib Plus Weekly Paclitaxel in Patients With Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
Latest Information Update: 04 Sep 2023
At a glance
- Drugs Ibcasertib (Primary) ; Paclitaxel
- Indications Carcinoma; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms CHIPRO
- Sponsors Chipscreen Biosciences
- 29 Aug 2023 Planned primary completion date changed from 31 Jul 2023 to 31 Dec 2024.
- 07 Mar 2022 Status changed from not yet recruiting to recruiting.
- 16 Jun 2021 New trial record